BioCardia (BCDA) Competitors $1.42 +0.10 (+7.58%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.41 -0.01 (-0.56%) As of 09:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. AKTX, PYRGF, IMA, CVKD, ALVR, DARE, KLTO, RNTX, KZR, and PASGShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Akari Therapeutics (AKTX), PyroGenesis Canada (PYRGF), ImageneBio (IMA), Cadrenal Therapeutics (CVKD), AlloVir (ALVR), Dare Bioscience (DARE), Klotho Neurosciences (KLTO), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Its Competitors Akari Therapeutics PyroGenesis Canada ImageneBio Cadrenal Therapeutics AlloVir Dare Bioscience Klotho Neurosciences Rein Therapeutics Kezar Life Sciences Passage Bio BioCardia (NASDAQ:BCDA) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Do analysts recommend BCDA or AKTX? BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 1,660.56%. Akari Therapeutics has a consensus price target of $3.30, suggesting a potential upside of 223.53%. Given BioCardia's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioCardia is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk & volatility, BCDA or AKTX? BioCardia has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Which has better earnings & valuation, BCDA or AKTX? BioCardia has higher revenue and earnings than Akari Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$60K137.50-$7.95M-$1.85-0.77Akari TherapeuticsN/AN/A-$19.79MN/AN/A Do insiders and institutionals hold more shares of BCDA or AKTX? 20.6% of BioCardia shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 20.0% of BioCardia shares are owned by insiders. Comparatively, 38.1% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer BCDA or AKTX? In the previous week, Akari Therapeutics had 3 more articles in the media than BioCardia. MarketBeat recorded 4 mentions for Akari Therapeutics and 1 mentions for BioCardia. BioCardia's average media sentiment score of 0.60 beat Akari Therapeutics' score of 0.33 indicating that BioCardia is being referred to more favorably in the media. Company Overall Sentiment BioCardia Positive Akari Therapeutics Neutral Is BCDA or AKTX more profitable? Akari Therapeutics' return on equity of -78.03% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets BioCardiaN/A -19,117.42% -246.92% Akari Therapeutics N/A -78.03%-31.62% SummaryBioCardia beats Akari Therapeutics on 8 of the 13 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.67M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-0.7721.5785.6527.61Price / Sales137.50271.42538.60201.06Price / CashN/A47.1237.9261.55Price / Book7.8910.1412.966.76Net Income-$7.95M-$52.31M$3.30B$275.88M7 Day Performance5.19%5.14%4.32%2.81%1 Month Performance-32.70%14.68%9.47%9.24%1 Year Performance-47.01%30.98%84.27%35.42% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.6372 of 5 stars$1.42+7.6%$25.00+1,660.6%-46.4%$7.67M$60K-0.7740Analyst ForecastAKTXAkari Therapeutics2.7278 of 5 stars$1.02+5.2%$3.30+223.2%-66.2%$31.64MN/A0.009Analyst ForecastGap DownPYRGFPyroGenesis CanadaN/A$0.17+2.0%N/A-69.1%$31.47M$9.14M-2.8090IMAImageneBio2.9016 of 5 stars$7.70-0.1%$35.50+361.0%-59.5%$30.88M$9.16M-1.0070Negative NewsShort Interest ↑CVKDCadrenal Therapeutics2.3952 of 5 stars$13.42-4.3%$32.00+138.5%+12.8%$28.72MN/A-1.514Analyst ForecastALVRAlloVirN/A$5.61+17.6%N/A-57.7%$28.29MN/A-0.28110High Trading VolumeDAREDare Bioscience1.9085 of 5 stars$2.09flat$10.00+378.5%-29.8%$28.17M$10K-0.9830Positive NewsAnalyst ForecastKLTOKlotho Neurosciences0.6456 of 5 stars$0.51+11.3%N/AN/A$27.91MN/A-1.12N/AAnalyst ForecastRNTXRein Therapeutics3.0726 of 5 stars$1.15-2.5%$10.00+769.6%N/A$27.50MN/A-0.439News CoverageAnalyst ForecastKZRKezar Life Sciences3.5396 of 5 stars$3.59-1.6%$9.00+150.7%-44.2%$26.73M$7M-0.3760Positive NewsAnalyst ForecastPASGPassage Bio3.299 of 5 stars$8.14+1.8%$75.67+829.6%-32.4%$25.43MN/A-0.45130Analyst Forecast Related Companies and Tools Related Companies AKTX Alternatives PYRGF Alternatives IMA Alternatives CVKD Alternatives ALVR Alternatives DARE Alternatives KLTO Alternatives RNTX Alternatives KZR Alternatives PASG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
